Denali Therapeutics Inc. is maintained at a Strong Buy rating, driven by progress in its MPS II [Hunter Syndrome] program with tividenofusp alfa. Despite discontinuing ALS efforts, DNLI's BLA for tividenofusp alfa is under FDA Priority Review under Accelerated Approval pathway, with PDUFA date extended to April 5, 2026. Company's ETV platform enables expansion into additional lysosomal storage disorders, with DNL126 for MPS IIIA offering near-term catalysts and proof of platform versatility.
A smart beta exchange traded fund, the WisdomTree Global ex-U.S. Quality Dividend Growth ETF (DNL) debuted on 06/16/2006, and offers broad exposure to the World ETFs category of the market.
Launched on 06/16/2006, the WisdomTree Global ex-U.S. Quality Dividend Growth ETF (DNL) is a smart beta exchange traded fund offering broad exposure to the World ETFs category of the market.
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| TJD Thomas John Drogan PR Inc.IPAL SECURITIES Inc. | 8,431 | $333,032.12 | $385,085.92 | $52,053.8 | 15.63% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 59 | $2,122.82 | $2,694.82 | $572 | 26.95% |
| AC Adam Claypool First Community Trust Na | 1,500 | $41,250 | $68,497.5 | $27,247.5 | 66.05% |
Kyle P. Smith NewEdge Wealth LLC | 51,503 | $1.92M | $2.34M | $424,709.11 | 22.16% |
| SS Sandra Stickney Collaborative Wealth Managment Inc. | 59,333 | $2.02M | $2.71M | $693,467.09 | 34.4% |
| ARCA Exchange | US Country |
The described entity operates as an investment fund, focusing predominantly on holding a portfolio that mirrors the composition and performance of a specifically defined index. This index is characterized principally by dividend-paying, growth-oriented common stocks located outside of the United States. By adhering to a fundamentally weighted approach, the fund aims to replicate or closely match the economic characteristics of its index constituents. This investment strategy highlights a preference for international equities that promise growth through dividends, differentiating it from diversification-based or domestic equity-centered funds. Notably, the fund maintains a non-diversified status, indicating a concentrated investment in the assets that align with its core strategy, rather than spreading the investment across a wide array of securities.
This product focuses on investments that are aimed at closely mirroring the components and performance of the fund's underlying index. It involves allocating at least 95% of the fund's total assets - excluding any collateral from securities lending - toward securities that are part of the index or possess economic characteristics nearly identical to those index constituents. This strategy seeks to provide investors with returns that reflect the performance of dividend-paying, growth-oriented global stocks outside the U.S.
The core of this service is the fund's investment approach, which relies on a fundamentally weighted index of global ex-U.S. common stocks exhibiting growth characteristics through dividend payments. The methodology behind the selection and weighting of stocks aims at capturing the economic essence of its constituents, potentially offering a strategic advantage in international equity markets. It underscores the fund's pursuit of growth through dividends outside the traditionally more volatile growth stock sectors.